Related references
Note: Only part of the references are listed.Role of multiparametric prostate MRI in the management of prostate cancer
Luke P. O'Connor et al.
WORLD JOURNAL OF UROLOGY (2021)
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
Felix Y. Feng et al.
JAMA ONCOLOGY (2021)
Epidemiology and Prevention of Prostate Cancer
Giorgio Gandaglia et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial
Zachary S. Zumsteg et al.
JAMA NETWORK OPEN (2020)
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial
Dario Pasalic et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer The NRG Oncology RTOG 0126 Randomized Clinical Trial
Jeff M. Michalski et al.
JAMA ONCOLOGY (2018)
Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database
Lindsay M. Burt et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens
Paul L. Nguyen et al.
EUROPEAN UROLOGY (2017)
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Michel Bolla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910
Thomas M. Pisansky et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy
Zachary S. Zumsteg et al.
EUROPEAN UROLOGY (2013)
LACK OF BENEFIT FOR THE ADDITION OF ANDROGEN DEPRIVATION THERAPY TO DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
Daniel Krauss et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
James W. Denham et al.
LANCET ONCOLOGY (2011)
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Christopher U. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy
GS Merrick et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - A randomized controlled trial
AL Zietman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy
DC Beyer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial
AV D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Prognostic importance of Comorbidity in a hospital-based cancer registry
JF Piccirillo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume?
LL Kestin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Share Paper
